PAKISTAN
VETERINARY
JOURNAL
     
 
previous page   Pak Vet J, 2026, 46(8) 1883-1892   next page
 
Immunogenic Cell Death in Canine Lung Cancer: A Comparative Veterinary Oncology (Review of Animal Models and Human NSCLC)
 
Hangao Sun1, Qing He2, Ziye Zhu2 and Yuju Bai1*

1Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563006, China; 2College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China; 2College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China

*Corresponding author: byj666188@163.com

Abstract   

Primary canine lung carcinoma is uncommon but clinically aggressive and may provide a spontaneous, immunocompetent model for human non-small cell lung cancer (NSCLC). This review evaluated evidence that targeted therapies induce immunogenic cell death (ICD) across human, canine, and murine lung cancer models and examined conserved tumor-microenvironment barriers to ICD-driven immunity. PubMed, Scopus, and Web of Science were searched for peer-reviewed studies published from January 2000 to June 2026 that assessed canonical ICD hallmarks—calreticulin exposure, ATP release, HMGB1 release, or type I interferon signaling—after targeted therapy. Eligible studies were synthesized narratively and comparatively. Seventy-five studies were synthesized. Results are organized into five thematic areas: (1) canine lung carcinoma as a spontaneous veterinary disease model, (2) veterinary and companion-animal evidence relevant to ICD, (3) human NSCLC evidence as a comparative reference, (4) conserved immune and stromal barriers across species and (5) animal-model evidence informing future veterinary trials. The synthesis reveals that while the molecular machinery for ICD induction and sensing is highly conserved, the tumor microenvironment—dominated by macrophage-mediated efferocytosis—constitutes the critical rate-limiting checkpoint for translating ICD into anti-tumor immunity across all species examined. Available evidence supports cross-species conservation of major ICD pathways and suggests that canine lung cancer may be useful for investigating mechanisms that limit ICD-driven immunity. Nevertheless, the reproducibility, clinical relevance, and therapeutic benefit of combining ICD-inducing agents with microenvironment-targeted treatments in dogs remain uncertain and require validation in larger, controlled prospective studies.

To Cite This Article: Sun H, He Q, Zhu Z and Bai Y, 2026. Immunogenic cell death in canine lung cancer: a comparative veterinary oncology (Review of animal models and human NSCLC). Pak Vet J, 46(8): 1883-1892. http://dx.doi.org/10.29261/pakvetj/2026.199

 
 
   
 

ISSN 0253-8318 (Print)
ISSN 2074-7764 (Online)



scopus
 
DOI
 
DOAJ SEAL
  
SCImago Journal & Country Rank